Features Screener Stocks Charts
Sign In Sign Up

Syngene Fundamental Analysis Revenue, Profits & Valuation

NSE: SYNGENE | BSE: 539268 | MISCELLANEOUS
Price ₹438.10 ₹2.75 (-0.62%)
P/E Ratio 35.5 TTM
52-Week Range
Low ₹380 High ₹729
Market Cap ₹176.26B Billion
ROE 10.5% Annual

Market data as of Jun 3, 2026

Here is a data-driven look at Syngene (SYNGENE), covering financial performance, valuation, and shareholding trends.

Syngene Revenue Trend

At ₹3,714 Cr, Syngene's FY2025 revenue was 3.8% ahead of the ₹3,579 Cr posted in FY2024.

The bigger picture is compelling: a 15.8% annual growth rate over 10 years took revenue from ₹860 Cr to ₹3,714 Cr.

With a top line of ₹3,714 Cr, Syngene operates at a mid-sized scale within the miscellaneous sector.

Revenue has moved in the same direction for 10 years running, suggesting the growth trend has structural legs.

Revenue Trend
YearRevenueYoY %
FY2025₹3,714 Cr+3.8%
FY2024₹3,579 Cr+9.7%
FY2023₹3,264 Cr+22.8%
FY2022₹2,657 Cr+18.1%
FY2021₹2,249 Cr
Revenue Trend (₹ Cr)

View Syngene's full 10-year revenue trend with CAGR analysis →

Syngene Profitability

The bottom line took a hit: Syngene's net profit slipped 2.7% to ₹496 Cr in FY2025.

Margins came under pressure in FY2025, with net profit margin dropping to 13.4% from 14.2%.

At ₹12.34 per share (diluted), FY2025 earnings were down year-over-year from ₹12.69.

Net Profit Trend (₹ Cr)

Is Syngene Undervalued

The P/E Ratio valuation pegs Syngene's fair value at ₹720, which is 64.4% upside from the current price.

Syngene shares are currently trading at ₹438.10.

Craytheon also calculates intrinsic value using the EPS Growth and DCF models. The full breakdown with assumptions is available in the detailed analysis.

Valuation Models
ModelEst. Fair Valuevs. Current Price
P/E Ratio₹72064.4% upside to fair value
EPS GrowthUpgradeUpgrade
DCFUpgradeUpgrade

See all valuation models for Syngene with detailed assumptions →

Syngene Shareholding Pattern

At 52.7%, the promoter stake has been flat for the past 4 quarters.

On the foreign institutional side, the holding is 13.9% as of March 2026 — down from 16.5%.

The DII stake stands at 26.4% as of March 2026, versus 24.1% in the year-ago period.

Shareholding Pattern (Last 4 Quarters)
QuarterPromoterFIIDIIPublic
Mar 202652.7%13.9%26.4%6.7%
Dec 202552.7%15.0%25.8%6.2%
Sep 202552.7%16.3%24.6%6.1%
Jun 202552.7%16.5%24.1%6.5%

Track quarterly shareholding changes for Syngene →

Syngene Balance Sheet

Proportional view as of 3 Jun 2026. Hover blocks for details.

Assets

Liabilities & Equity

FY2025 total assets: ₹67.96B (up 10.5% YoY from ₹61.52B).

Top categories: Property, Plant & Equipment (52.7%), Other Assets (19.4%), Cash & ST Investments (14.4%).

Of the ₹67.96B in liabilities and equity, 69.6% is shareholder equity, 8.5% is interest-bearing debt, and 21.9% is operating liabilities. Over the year, debt is up 4.1% and equity is up 11.0%.

Balance sheet composition — FY 2025

Assets (values in Indian Rupees, with M = millions, B = billions)
CategoryValue
Cash & ST Investments 9.78B
Receivables 5.27B
Inventories 1.56B
Property, Plant & Equipment 35.84B
Investments 2.07B
Intangibles & Goodwill 256.00M
Other Assets 13.20B
Liabilities and equity (values in Indian Rupees, with M = millions, B = billions)
CategoryValue
Equity 47.27B
Short-term Debt 1.69B
Long-term Debt 4.09B
Trade Payables 3.52B
Other Liabilities 11.39B

View full balance sheet (multi-year) →

Syngene — The Bottom Line

What should investors take away from Syngene's (SYNGENE) latest numbers? Here's the summary.

Revenue of ₹3,714 Cr in FY2025, up 3.8% year-over-year.

Long-term revenue has been compounding at 15.8% annually over 10 years.

The company is profitable, with a net margin of 13.4% and net income of ₹496 Cr.

The P/E Ratio model implies 64.4% upside to fair value from the current price. The remaining two models are worth cross-checking before drawing a conclusion — sign up to see the full analysis.

Unlock Full Analysis

For the complete 10-year financial history with interactive charts and growth analysis, explore Syngene's detailed profile on Craytheon.

Related Stocks